A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC) (MOUNTAINEER) Meeting Abstract
| Authors: | Strickler, J. H.; Niedzwiecki, D.; Zemla, T.; Cercek, A.; Fakih, M.; Ng, K.; Sanchez, F. A.; Wu, C. S. Y.; Peterson, S.; Bandel, L.; Grothey, A.; Bekaii-Saab, T. S. |
| Abstract Title: | A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC) (MOUNTAINEER) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 196s |
| Language: | English |
| ACCESSION: | WOS:000411895707105 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.TPS3624 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS3624 -- Source: Wos |
